As of 6 Nov 2026, Norris Medicines is loss-making on a trailing 12-month basis, with a net loss of ₹0.37 Cr, so it has no P/E ratio. The share price is ₹15.00, 25% below its 52-week high. Its net worth is negative, as liabilities exceed assets, and borrowings are ₹22 Cr. It is a small-cap company with a market cap of ₹15 Cr, ranked 145th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares fell 7.4% over the past year.
- ₹15.37
- ₹15.49
- ₹15.00
- ₹15.37
- 102
Health check
- ReturnsBehind
−7.4% over a year, better than 0 of 7 peers.
- Price tagNegative equity
Book value is below zero, so P/E and P/B mislead here.
- Growthn/a
Not enough yearly results to measure.
- ProfitabilityDistorted
With negative net worth, return ratios are meaningless.
- Balance sheetStretched
Negative net worth: liabilities exceed assets.
- Red flags3 to check
Loss-making over the last twelve months.
Small cap
Market sensitivity
Key metrics
- Market cap
- ₹15 Cr
- Small cap
- P/E
- n/a
- Industry 28.7
- Price to book
- −1.00
- Peers 4.99
- Dividend yield
- 0.00%
- ROE
- n/a
- Peers 14.7%
- ROCE
- n/a
- Peers 17.9%
- Debt to equity
- n/a
- Debt ₹22 Cr
- EPS (TTM)
- n/a
- OPM (TTM)
- −42.9%
- Net margin −4.8%
- Sales growth
- −36.5%
- Latest quarter vs a year ago
- Profit growth
- n/a
- Year-ago quarter not reported
- Price to sales
- 1.97
- EV/EBITDA 69.4
Strengths and risks
Risks to check
- Loss-making over the last twelve months.
- Negative net worth: liabilities exceed assets.
- Quarterly sales down 36.5% on a year ago.
About Norris Medicines
Norris Medicines Limited manufactures and sells pharmaceutical formulations in India. The company offers nonsterile dosage products, such as tablets, capsules, liquid orals, and copical ointments, as well as injections and medicinal formulations. Its products include antibiotics, anti-inflammatory/pain management, dermatology, antiemetic, nutrition, gastro, cough/cold, skin and allergy, antimalarial, diabetic, cardiac, anti-malarial, dental, and other…
- Headquarters
- Ankleshwar
- Employees
- 18
- Sector
- Healthcare
- ISIN
- INE744C01029
- Website
- norrispharma.com
Price range
- Avg volume (3M)
- 835
- 1-year return
- minus 7.4%
- From 52-week high
- minus 25.2%
Peers · Drug Manufacturers - Specialty & Generic
| Company | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMASun Pharmaceutical Industries | 1,860.00 | plus 1.69% | 4,46,276 | 40.7 | 4.99 | 17.9% | 13.1% | 28.2% | 10.4% | 10.6% | 0.86% | plus 8.2% |
| DIVISLABDivi's Laboratories | 10,320.50 | plus 1.78% | 2,73,977 | 93.6 | 16.35 | 19.0% | 16.2% | 34.9% | 11.0% | 12.1% | 0.29% | plus 49.0% |
| TORNTPHARMTorrent Pharmaceuticals | 4,750.00 | plus 0.85% | 1,80,675 | 80.2 | 9.83 | 9.1% | 15.7% | 33.7% | 13.3% | 20.2% | 0.80% | plus 31.7% |
| LAURUSLABSLaurus Labs | 2,340.00 | minus 0.26% | 1,26,433 | 94.4 | 20.86 | 19.5% | 24.0% | 30.4% | 3.8% | 4.0% | 0.09% | plus 138.6% |
| ZYDUSLIFEZydus Lifesciences | 1,197.90 | plus 0.41% | 1,19,491 | 28.6 | 4.29 | 19.0% | 14.7% | 26.2% | 16.5% | 37.0% | 0.08% | plus 22.8% |
| DRREDDYDr. Reddy's Laboratories | 1,373.00 | plus 0.51% | 1,14,462 | 40.9 | 2.96 | 14.2% | 7.3% | 15.9% | 11.0% | −1.7% | 0.58% | plus 13.8% |
| CIPLACipla | 1,411.00 | plus 0.49% | 1,13,993 | 39.4 | 3.22 | 14.9% | 8.3% | 17.3% | 7.2% | 11.5% | 0.92% | minus 6.6% |
| NORRISNorris Medicines | 15.00 | minus 2.41% | 15 | – | −1.00 | – | – | −42.9% | – | – | 0.00% | minus 7.4% |
| Median of 7 peers | – | 0.51% | 1,26,433 | 40.9 | 4.99 | 17.9% | 14.7% | 28.2% | 11.0% | 11.5% | 0.58% | 22.8% |
Quarterly results
This company doesn’t report these figures in a format we can read yet.
Profit & loss
This company doesn’t report these figures in a format we can read yet.
Forecast
Balance sheet
This company doesn’t report these figures in a format we can read yet.
Cash flow
This company doesn’t report these figures in a format we can read yet.
Shareholding pattern
This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders.
Major shareholders
Filings & events
News
No recent news coverage found.